call 1.800.directv >>> we have an earnings alert on gilead >> the q and a on gilead's call going on right now the ceo talking with analysts. one thing people are trying to get a hold of is the future of its hepatitis c franchise. the stock went down after-hours. potentially under 2018 forecast. big questionfor gilead of course is how are they going to return to growth and a lot of that could potentially come from m and a. gilead says it's going the repatriate $28 billion in crash this year. a big question people have is what are they potentially going to by. gilead and gel gene have been the most aggressive management teams talking about m and a this year and celgene just did two big deals. gale yad was asked about the technologies he wanted to bring in jeeb editing companies, he highlighted four companies, all between 1.4 and $2 billion in market cap they named blue bird by yoes and spark therapeutics both in one time gene therapy treatments intercept. they are in liver diseases and biomarin a bigger company in liver disease. these are all names that gilead is potentially looking at. >>

gilead's results are out meg joins us. >> it was a beat for gilead in the fourth quarter, coming in asersus estimate of $1.67 revenue at $5.59 billion versus estimate of $5.4 billion we look at the health of their hepatitis contract franchise, in line with estimates at $1.5 billion total versus estimates of $1.47 billion the stock is down right now, though, because they diplomat put this in the release. if you look at the slides up ahead of their 4:30 conference call they gave 2018 forecasts for that hepatitis c franchise of around $3.5 to $4 billion for 2018 that's short of the $4 billion the street was looking for the company breaking out a lot of expectations for taxes in terms of 2018. they say their tax rate will be 21% to 23%, basically in line with expectations. they say they expect to repatriate $28 billion within this year. they are taking a $5.5 billion charge in the fourth quarter related to tax reform, not in the adjusted eps numbers we gave you. the company raising their dividend by 10%. you are seeing gill yard weaker, down 3%, probably because of the 2018 hepatitis c for

the drug company who own those drugs, principally gilead, has priced it out of reach for many programs especially public , programs. we have folks that could be cured, who aren't being cured because the price is too high. host: what about the access to pain medication and the impact that the efforts to cut down on opioids has had on patients who use it correctly and need it? guest: i am not an expert on opioid addiction. and i believe that we need steps, better steps to track the distribution of drugs, how are they getting into people's hands, prescribing patterns, dispensing patterns by pharmacies and people who have addiction need appropriate treatment. that could be treatment at treatment centers, drugs that help wean people off of addictive drugs, we need both those things. we need to make sure we're cracking down on the supply and supporting people who are trying to fight their addiction. host: the group is patients for affordable drugs, patient theforaffordabledrugs.org, david mitchell is president and founder. appreciate the time. >> we are live in little rock arkansas for the n

but the drug companies who own those drugs, gilead, has priced it out of reach for public programs. we have folks but could be cured, but aren't because the price is too high. host: what about the access to pain medication and the impact that the efforts to cut down on opioids has had on patients who use it correctly and need it? i am not an expert on opioid addiction. believe that we need better steps to track the distribution of these drugs, how they are getting into people's hands, prescribing patterns by doctors, dispensing patterns by pharmacies, so we can get a better handle on it. people who have addiction need appropriate treatment area that could be treatment -- people who have addiction need appropriate treatment. we can take them off of different drugs. we need to make sure they are cracking down on the supplies, but also supporting people who are trying to fight their addiction. host: the group is patients for affordable drugs. patients444 drugs.org. thank you for your time. guest: thank you for having me. request to budget congress, one of the topics we may hear about d

when we started the program there was one drug company, gilead. when others enter the market with a similar type crisis it dropped. we now work with and use multiple drug companies. the prices are less than half of when we started this program. it allows us to be able to reach out more. and get this done even faster. interesting thing that we are finding is there is a population of veterans that while they could be cured are choosing not to take the drug. we can offer some veterans homes. a small number but it is not insignificant. we are trying to understand how we can do better with that with the general community. i think it's going to be a problem with the general community as well. >> thank you very much for being with us. talked about the appeal process and reviewing files. i absolutely urge that be engaged on an ongoing basis. clearly separated people from the military service primarily due to mental health challenges. and leads to suicide and other behaviors. we very much appreciate the assistance. one to three to end homelessness among ve

akamai, gilead sciences, and tesla. mbi had its worst week since october 2016.ressured in part by president donald trump talking about bringing done drug pricing. care we had the drug consortium between jpmorgan, berkshire hathaway. a possible bright spot, we have twitter. is technically confirmed for a big new hire. bloomberg does have a breaking news network with twitter, on twitter, tick tock. next week, the report earnings. perhaps they could meet, maybe e ven beat. abigail doolittle covering a offer us in new york. thanks so much for breaking it all down. in the latest revolving, door sony will promote the ceo after helping to restore earnings of the japanese electronics icon. him bring discipline to the giant after years of losses. he will become sony chair april 1. coming up, cryptocurrencies keeps lighting. the coin and its increasing board of rivals continue 2018 in the red. more concerns ahead next. bloomberg technology is livestreaming on twitter. tech us out 5:00 p.m. in new york, to clock p.m. in san francisco. this is bloomberg. ♪ emily: ubs could

. >>> gilead posting a fourth quarter loss on a charge related to the new taxing law. the company says sales of its flagship hepatitis c drugs fell more than half and it sees a further slowdown this year >>> chipotle's fourth quarter results beating analyst estimates. the chain is working to regain customers trust following several safety food issues over the last several years down 7% in the premarket >>> lululemon announced on monday that the ceo resigned saying he fell short of the company's standards of conduct sources say one issue that led to the departure was a multi-year relationship with a fee mral desimale designer of ty lululemon did not renew her contract last month. he also had a negative impact on the company's culture, which they described as toxic. a company spokesperson says any time violations of policies are brought to their attention, they take appropriate action. it fell on monday but recovered since then. >>> still ahead, we're headed to london for the latest action in european markets. >>> and later, spacex launching the most powerful rocket it e

turning positive as well a lot coming from strong earnings they're putting money into new technology gileadentsabove estimates. traders saying we are seeing flow come into big growth reliable names but that's not necessarily translating to all names. apple in the red as has alphabet, and they're back in correction territory facebook also trying to move higher micron one of today's big winners. tech stocks have been the leaders in terms of tech but in the last week, they've only been up one of five sessions, we'll see if they can pull off a second one today, up better than 4% since last month. back to you. >> the nasdaq is lagging a little dow is strong. up 375 thank you. bertha coombs. >>> steve liesman has headlines from chicago from evans. >> evans saying the fed should keep policy on hold until midyear. evans, chicago fed president, one of two dissenters for the december rate hike he is dovish, not in a hurry to raise rates. he supports the idea of median long rate funds of 2.8%. not in a hurry to get there. he is concerned about persistent factors holding down inflation rate he says the

essentially they ruled against that but on a narrower ground they could have but the best point justice gilead wrote the most effective opinion why they were fair and equitable so he had some difficulty to come around and wrote the strongest defense in the 80s. it appears they wrote a broad opinion each giving deep skepticism but then he saw the light as time went on steroids you have any idea what they would do is there wiggle room but the language goes right up the line. you could have just distinguished to say we don't have to addressth that but going out of his way not was directed at him in the court went out of their way to project those arguments not me personally bet the brief that went out of its way for those arguments for understandable reasons. >> what happens if there is a federal statute? >> i don't know the answer to that challengers have been very careful but it is harder to balance but as the case has wbeen positioned they were careful not to look like they're asking for anything more. >> we were asked that question in oral argument ined friedrich it isn't completely obvious b

when we started this program, there was one drug company, gilead. the price was pretty high. v.a. does better than anybody else in terms of pricing. but when others have entered the market with the similar type, the prices have dropped. we now work with and use multiple drug companies. the prices are less than half of when we started this program. it just allows us to be able to reach out more and get this done even faster. so the interesting thing that we're finding is that there is a population of veterans that while they could be cured are choosing not to take the drug. we're trying to understand that. it's sort of like what we find in homelessness. even though we can offer some veterans homes, they want to stay out on the streets. small number, but it's not insignificant. and so we're trying to understand how we can do better with that. we share our lessons with the general community, because i think it's going to be a problem in the general community as well. >> thank you very much for being with us and sharing some of the data. i know on one of the slides you talked about th

over the last couple of weeks it's been extraordinary to the upside i'm not in this, i'm in gilead, i'mene >> why was bristol a dud last year >> the market killed it. >> it had a couple of huge setbacks along the way, scott, where the stock got absolutely crushed on a couple of occasions that they couldn't recover from. >> the trade yesterday, and i took advantage of part of it, was nectar, which it put 2 billion into that stock was down news, which seemed ridiculous. i sold it, i just happened to be in the office. that's the kind of stuff you'll continue to see. that's why biotech is going to continue to move every drug company, amgen, you name it, has said, i'm buying, i want to make some acquisitions >> i think the name i'm in, stephanie link got me in, the growth att abvie is phenomenal >>> coming up, the controversy over chipotle. it's not theirs. it's mine. mine. mine. and it always will be, forever and forever. the new rx 350l with three rows for seven passengers. experience amazing at your lexus dealer. the markets change... at t. rowe price... our disciplined approach remains.

. >> gilead.ck as down then moved up huge options today i think it's guying higher. >> karen. >> big rotation out of fang today. i think it's time for apple. right here. >> time for apple. >> i like that >> good stuff today. >> letter x, starting to move again. >> u.s. steel? >> yes >> binary. cme, with volatility, about, the chicago mercantile exchange llould do we >> 23 degree >>> my mission is simple, to make you money i'm here to level the playing field for all investors. there's always a bull market somewhere, and i promise to help you find it. "mad money" starts now >>> hey, i'm cramer. welcome to "mad money. welcome to cramerica other people want to make friends. i'm just trying to make you some money. my job is not just to entertain but to educate and teach talking about a crazy day like today. so call me at 1-800-743-cnbc or tweet me @jimcramer. say hello to the new new normal.

gilead said the patent was invalid. ceo's tenure missed targets. your business flash update. julia: let's stay in the world of banking. earlier on bloomberg, the section ceo discovered how european banks are faring now. oudea: we suffered from volatility in global markets that was not good. we entered into something of a progressive normalization. the normalization of the monetary policy, the central bank, i think we are exiting. david: how are you position your bank to take the most advantage without having undue risk? frederic: we are building businesses for the long-term, in which our client-driven. we have in equity derivatives to categories of activities -- structured products that are updated for investors. they are not that sensitive to the volatility. they are fundamentally meeting client demand. then the volume business. to see toll environment better volumes, particularly on the equity derivative said. al: are you taking on more alix: i've taken a more risk? they would be either decreased or remain steady. frederic: they are remaining low

the drug company who own those drugs, principally gilead, has price today out of reach for programs,specially public programs. we have folks that could be ured, who aren't being cured because the price is too high. host: what about the access to medication and the impact on the efforts to cut down opioids has had on patients who need it?rrectly and guest: i am not an expert on addiction. we need ieve that steps, better steps to track the are ibution of drugs, how they get intoing people's hands, escribing patterns, dispensing atterns by pharmacys and people who have addiction need appropriate treatment, that could be treatment at treatment centers, drugs that help wean people off of addictive drugs, we need both things. we need to make sure we're cracking down on the supply and who are tryingle addiction.heir is patients for affordable drugs, patient theforaffordabledrugs.org, david mitchell is president and founder. appreciate the time. "washington journal," open phones for our last 20 minutes today. any public policy issue you want about, the phone lines are yours, the numbers are

shares of gilead are lower in extended trade.arma company seized up to $20 billion of product sales with growth margins of up to 87%. fourth-quarter adjusted eps topping the average estimate at $1.78. revenue beating the street at $5.95 billion. shazame takeover of shoul may run afoul of regulators. apple would be ordered to file the deal with antitrust authorities in brussels. having almost missed facebook's acquisition of whatsapp, they want to change the rules on takeovers of companies that make no money but hold valuable intellectual property. suffered any setback last month when a u.s. carrier scrapped an order for 40 jets. the first order cancellation for the mitsubishi regional jet follows repeated delays and has pushed back the first delivery mid 2020.rs to let's cross over to the singapore airshow where haslinda amin is standing by with the companies sales and marketing vp. haslinda. haslinda: yvonne, we are talking about the emaar j -- mrj. it does seem like it is coming online. good to have you with us. was meant to ta

enough dowdupont capital sold entire ge investment more than 103,000 shares general electric most gileadfed i thought very interesting, so that is what they are doing at dupont capital in latest quarter. >> thank you nicole all eyes on technology, amazon alphabet apple all delivers quarterly results for busy period and, of course, includes holiday season coming after the bell will one technology giant rise before the rest joining us "varney & company"host you are calling it amazon day. >> i am, i am continually astonished about this company power influence excitement in overly economy certainly stock market look at that close premarket, 1451 dollars per share did you know a year ago, it was 803 dollars? it has gone up what 600 bucks, in space of past year. it has got a price earnings ratio i don't deal in poe.'s. >> i know the noises you said p.e., we are running you are not getting buzz i go say one thing getting buzzed all over. >> i am your buzzer. >> thank you. thank you, okay you can continue now. >> pe is an astronomical -- >> [buzzer]. >> astronomical 369 no yield pays no dividend

amgen, biogen, celgene and gilead amgen having a lot of impact from taxes announcing a new $10 billion buyback. a lot wondering if amgen will be a big buyer. i'm hearing this is a defensive play earlier in the week, you already saw health care stocks sell off on the amazon/berkshire hathaway/jpmorgan consortium news >> that's a great point. thanks for staying meg talking about some of those health care movers what does jump out to you about what's different in this decline -- there was a cycle when biotech would have led us up or down and it's not that way today. >> or one group beneficiary of the turmoil and today that's not that day today 90% of the decline was in declining stocks these lopsided washout days, net basis longer term, they're probably good news if you're looking for signs. and health care is one of those groups that often would have been, fine, we'll get a bid, we'll buy the big pharma because -- >> i was thinking of you with the energy did you see exxon -- >> clobbered. >> for a while it was the worst performer in the s&p 500. >> it was weird. year to date, energy up u